Name: Medical Laboratories Stocks in USA: Revenue Cohort 1 comparison snapshot
Creator: Fliar BI Prism

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DGX · NYSE

Quest Diagnostics

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 1967WILMINGTON$26.52B market cap

View full Companies Radar profile

53Moderate

Snapshot price$240.3as of page date

Monthly-close return+65.4%five-year window

FY2025 revenue$11.04BQUEST DIAGNOSTICS INC

Net margin9.0%FY2025

P/E snapshot25.5xone ratio, not a verdict

Prism attention39.9%share across these five

Filing track recordRevenue, USD billions

+2.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 0.6%

52-week position91% through range

$171.2$247.2

News mentions10.7K

Community mentions1.8Kpartial coverage

U.S.-scope patents1945

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position30/100
Capital-event signal64/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 3 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 60 M&A involvements, 12 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2VCYT · Nasdaq

Veracyte

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2008San Francisco, California$3.47B market cap

View full Companies Radar profile

52Moderate

Snapshot price$43.19as of page date

Monthly-close return-7.0%five-year window

FY2025 revenue$0.52BVERACYTE, INC.

Net margin12.8%FY2025

P/E snapshot30.9xone ratio, not a verdict

Prism attention6.1%share across these five

Filing track recordRevenue, USD billions

+135.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 23.9%

52-week position44% through range

$29.38$60.91

News mentions1.7K

Community mentions21partial coverage

U.S.-scope patents221

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal74/100
Management stability90/100
Market position5/100
Capital-event signal67/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3RDNT · Nasdaq

RadNet

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 1988Bakersfield, California$5.97B market cap

View full Companies Radar profile

51Moderate

Snapshot price$75.82as of page date

Monthly-close return+158.7%five-year window

FY2025 revenue$2.04BRadNet, Inc.

Net margin-0.9%FY2025

P/E snapshot85.5xone ratio, not a verdict

Prism attention4.7%share across these five

Filing track recordRevenue, USD billions

+55.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 11.6%

52-week position71% through range

$50.82$85.84

News mentions1.3K

Community mentions44partial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal65/100
Management stability90/100
Market position25/100
Capital-event signal50/100
Innovation pulse9/100

Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 20 M&A involvements, 10 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4LH · NYSE

LabCorp

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 1969Burlington$26.98B market cap

View full Companies Radar profile

45Cautious

Snapshot price$332.7as of page date

Monthly-close return+37.6%five-year window

FY2025 revenue$13.95BLABCORP HOLDINGS INC.

Net margin6.3%FY2025

P/E snapshot27.5xone ratio, not a verdict

Prism attention37.0%share across these five

Filing track recordRevenue, USD billions

-0.2%

FY2020–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -0.0%

52-week position91% through range

$244.5$341.8

News mentions10.0K

Community mentions6.1Kpartial coverage

U.S.-scope patents0

Prism InsightsWhat sits behind the readiness signal
Observed risk 2/100higher means more observed risk

Earnings signal70/100
Management stability90/100
Market position33/100
Capital-event signal5/100
Innovation pulse9/100

Management signal

No leadership-churn flag in the model; 7 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 40 M&A involvements, 33 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5NTRA · Nasdaq

Natera

A U.S.-listed issuer classified by the SEC in Medical Laboratories

Founded 2004Redwood City, California$46.41B market cap

View full Companies Radar profile

42Cautious

Snapshot price$322.0as of page date

Monthly-close return+188.9%five-year window

FY2025 revenue$2.31BNatera, Inc.

Net margin-9.0%FY2025

P/E snapshot-3609.4xone ratio, not a verdict

Prism attention12.3%share across these five

Filing track recordRevenue, USD billions

+268.7%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 38.6%

52-week position89% through range

$157.4$343.2

News mentions3.3K

Community mentions436partial coverage

U.S.-scope patents631

Prism InsightsWhat sits behind the readiness signal
Observed risk 14/100higher means more observed risk

Earnings signal74/100
Management stability90/100
Market position12/100
Capital-event signal30/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 7 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 7 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Natera

+188.9%

RadNet

+158.7%

Quest Diagnostics

+65.4%

LabCorp

+37.6%

Veracyte

-7.0%

Latest revenue

USD billions, official filing scope shown on each company card.

LabCorp

$13.95B

Quest Diagnostics

$11.04B

Natera

$2.31B

RadNet

$2.04B

Veracyte

$0.52B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Veracyte

12.8%

Quest Diagnostics

9.0%

LabCorp

6.3%

RadNet

-0.9%

Natera

-9.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Quest Diagnostics

39.9%

LabCorp

37.0%

Natera

12.3%

Veracyte

6.1%

RadNet

4.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized medical laboratories news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Quest Diagnostics leads the conversation

It holds 39.9% of measured medical laboratories news attention and also carries the basket's largest revenue base at $11.04B.

Price path

Natera leads the available price paths

Its monthly-close return is +188.9% for the five-year window. At the other end, Veracyte is -7.0% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Veracyte has the widest latest margin

Its FY2025 net margin is 12.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Natera shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -3609.4x while its five-year window price return is +188.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DGX

Quest Diagnostics

10,725available Prism news records

Prism top themes

Earnings & financial performance

150

Price action & investor response

149

Macro demand & rates

84

Capital allocation & transactions

72

Leadership & governance

66

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+11.3%1,121 latest 12m vs 1,007 prior 12m

Machine-classified coverage tone

76.1% positive-9.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer screenings 65earnings report 46cancer biomarkers 43blood-based screening 39investment deal 38stock price 37stock performance 34share price 29

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · VCYT

Veracyte

1,655available Prism news records

Prism top themes

Earnings & financial performance

98

Price action & investor response

95

Capital allocation & transactions

38

Leadership & governance

14

Legal, arbitration & regulatory

8

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+50.6%351 latest 12m vs 233 prior 12m

Machine-classified coverage tone

96.7% positive+0.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer biomarkers 59stock performance 31age prostate cancer 24obesity prostate cancer 22biomarker discovery 20diet prostate cancer 20african ancestry prostate cancer 20vascetomy prostate cancer 19

Keyword tag occurrences in available Prism news records.

Coverage: 2010-06-10–2026-06-06 · trend and themes shown through 2026-06

Areas of research · RDNT

RadNet

1,265available Prism news records

Prism top themes

Earnings & financial performance

61

Capital allocation & transactions

42

Price action & investor response

42

Macro demand & rates

12

Leadership & governance

11

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+10.8%298 latest 12m vs 269 prior 12m

Machine-classified coverage tone

98.2% positive+5.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

radiology reporting 35nuclear medicine imaging 29ct scan interpretation 26mammography review 24radiology imaging services 22breast mri screening 21diagnostic imaging center 19ultrasound readings 19

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-16–2026-06-19 · trend and themes shown through 2026-06

Areas of research · LH

LabCorp

9,954available Prism news records

Prism top themes

Price action & investor response

172

Earnings & financial performance

135

Leadership & governance

86

Legal, arbitration & regulatory

74

Capital allocation & transactions

65

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+19.5%1,352 latest 12m vs 1,131 prior 12m

Machine-classified coverage tone

77.7% positive-4.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer biomarkers 47stock performance 35circulating tumor dna 31liquid biopsy sensitivity 29clinical trial outsourcing 28earnings report 27blood-based screening 26cancer screenings 26

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-26 · trend and themes shown through 2026-06

Areas of research · NTRA

Natera

3,318available Prism news records

Prism top themes

Price action & investor response

181

Earnings & financial performance

99

Capital allocation & transactions

57

Legal, arbitration & regulatory

49

Leadership & governance

9

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+122.6%875 latest 12m vs 393 prior 12m

Machine-classified coverage tone

90.2% positive+0.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cancer biomarkers 65circulating tumor dna 60stock performance 48investment deal 33biomarker discovery 26blood-based screening 25prenatal genetic testing 24ctdna analysis 24

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-15–2026-06-19 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DGX

Quest Diagnostics

1,837 mentions

Products, pricing and logistics

1,142

Workplace and hiring

209

Stock and valuation

125

Other company context

2

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,837 records remained after filtering.

RDNT

RadNet

44 mentions

Products, pricing and logistics

15

Workplace and hiring

10

Stock and valuation

9

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 44 records remained after filtering.

LH

LabCorp

6,120 mentions

Products, pricing and logistics

4,102

Workplace and hiring

571

Stock and valuation

176

Other company context

5

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 6,120 records remained after filtering.

NTRA

Natera

436 mentions

Products, pricing and logistics

244

Stock and valuation

33

Workplace and hiring

14

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 436 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DGX

Quest Diagnostics

through 2026-04-28

Earnings releases 40M&A 20Company announcements 9Leadership changes 7Asset acquisitions 6

2026-04-28
Company announcements
Quest Diagnostics on Tuesday announced the public offering of its 5 percent senior notes expected to bring in $500 million in net proceeds.
2026-04-22
Earnings releases
CFO Sam Samad reported consolidated revenue of $2.9 billion, up 9.2% year over year, with consolidated organic revenue up 9%.
2026-03-12
Leadership changes
Quest Diagnostics Incorporated (NYSE: DGX ), a leading provider of diagnostic information services, today announced that its board of directors has elected Timothy (Tim) Wentworth, a highly seasoned business leader, to serve as a director.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

VCYT

Veracyte

through 2026-02-25

Earnings releases 23Company announcements 2Leadership changes 2Listing / IPO 1

2026-02-25
Earnings releases
Total revenue for the fourth quarter of 2025 was $140.6 million , an increase of 19% compared to $118.6 million reported in the fourth quarter of 2024.
2025-02-14
Listing / IPO
Veracyte Inc. closed its public offering generating net proceeds of about $55.1 million.
2024-09-05
Leadership changes
Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, recently announced the appointment of Brent Shafer and Tom Miller, Ph.D., to its board of directors, effective immediately.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RDNT

RadNet

through 2026-03-23

Earnings releases 21Leadership changes 9M&A 8Asset acquisitions 5Company announcements 5

2026-03-23
Company announcements
RadNet’s 2026 guidance, as discussed during the event, includes imaging center revenue growth of 17% to 19% and imaging EBITDA growth of 18% to 22%, implying margin expansion.
2026-03-03
M&A
RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France.
2026-03-02
Earnings releases
For the fourth quarter of 2025, RadNet reported Total Company Revenue of $547.7 million and Adjusted EBITDA(1) of $87.7 million. Adjusting for unusual or one-time items impacting the fourth quarter, Total Company Adjusted Earnings(3) was $18.1 million and diluted Adjusted Earnings Per Share(3) was $0.23 during the fourth quarter of 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LH

LabCorp

through 2026-05-01

Earnings releases 27Asset acquisitions 25Leadership changes 14M&A 9Company announcements 5

2026-05-01
Earnings releases
Enterprise revenue reached $3.5 billion, increasing 6%.
2026-03-20
Asset acquisitions
Laboratory Corporation of America this week said it has completed its acquisition of select assets of Crouse Health's Laboratory Alliance of Central New York's laboratory business.
2026-02-13
Leadership changes
White will lead Labcorp’s global communications function, shaping and driving all enterprise, executive and business communications strategies to strengthen the brand’s reputation, engage stakeholders and advance business across internal and external audiences, according to the role’s job description.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NTRA

Natera

through 2026-04-09

Earnings releases 26Lawsuits 13Asset acquisitions 5Company announcements 2Listing / IPO 2

2026-04-09
Lawsuits
The Delaware court awarded the company a 30% ongoing royalty on post-injunction revenues tied to its MRD-related patents.
2026-04-04
Company announcements
On April 1, 2026, he executed three sales of 1,048, 1,000, and 952 shares at weighted average prices of $201.3206, $202.3638, and $203.3106 per share.
2026-02-26
Earnings releases
Generated total revenues of $665.5 million in the fourth quarter of 2025, compared to $476.1 million in the fourth quarter of 2024, an increase of 39.8%.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Medical Laboratories Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary medical laboratories news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

medical laboratory market

4 sources83.6% extraction confidence

2023 extracted base$16.36B

2027 extracted forecast$16.36B

Implied source CAGR12.6%

Understanding current healthcare trendspatient needsadvancements in medical technology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, ASEAN, Asia Pacific. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Medical Laboratories news pulse

74,006available Prism news records

Latest 12m volume+8.4%32238 vs 29751 records

Positive classified tone64.3%+5.4 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching laboratory, medical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,806

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,582

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Understanding current healthcare trends

4 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,806 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

5,614 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Economic-cycle exposure

6,746 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.4% news volume

The latest 12 months contain 32,238 matched records versus 29,751 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

64.3% positive · +5.4pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 8071 (Medical Laboratories), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 1–8. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Medical Laboratories Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 31 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Quest Diagnostics leads the readiness ranking

Its Prism readiness score is 53/100, the highest in this five-company comparison.

Open Quest Diagnostics in Companies Radar

Scale and margin leadership sit with LabCorp and Veracyte

LabCorp has the largest displayed latest revenue at $13.95B; Veracyte has the widest displayed latest margin at 12.8%.

Open LabCorp in Companies Radar Open Veracyte in Companies Radar

Comparisons

Strongest versus weakest available price path

Natera is +188.9% for its five-year window; Veracyte is -7.0% for its five-year window.

Open Natera in Companies Radar Open Veracyte in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $13.95B for LabCorp to $0.52B for Veracyte. Entity and filing-period labels remain visible on the company cards.

Open LabCorp in Companies Radar Open Veracyte in Companies Radar

Anomalies

LabCorp has the widest attention-readiness rank gap

It ranks #2 by measured news attention (37.0%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open LabCorp in Companies Radar

Veracyte shows a price-operating divergence to inspect

Its displayed filing-revenue change is +135.6% while its available monthly-close return is -7.0%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Veracyte in Companies Radar

Explanations

Attention measures coverage volume, not quality

Quest Diagnostics's 39.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Quest Diagnostics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Quest Diagnostics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 53/100 score.

Open Quest Diagnostics in Companies Radar

Stress-test the largest divergence before forming a view

Compare Veracyte's profile with Natera's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Veracyte in Companies Radar Open Natera in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.